Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of patients previously treated with autologous CAR T cells
2024-511684-28-00Phase 2Authorised
- Sponsor
- Autolus Therapeutics plc
- Start
- Jul 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of obecabtagene autoleucel and AUTO4 in B-cell malignancy, Immune disorder and Neoplasm, sponsored by Autolus Therapeutics plc. Primary endpoints: Incidence of serious adverse events related to AUTO CAR T cell therapy, New malignancies and 1 more. Planned start Jul 2024; status: authorised.
02
Drugs
obecabtagene autoleucelAUTO4
03
Conditions
B-cell malignancyImmune disorderNeoplasm
Beyond the preview
Go deeper on 2024-511684-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511684-28-00.